Intestinal Neoplasm

The CRYSTAL Phase III Trial evaluated efficacy of irinotecan, fluorouracil, and leucovorin (FOLFIRI) with or without Cetuximab for colorectal cancer patients who presented with unresectable metastatic… (full text at CIViC)

PMID 21502544 · Van Cutsem et al., 2011 · Open in CIViC

In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type. BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%… (full text at CIViC)

PMID 27404270 · Amaki-Takao et al., 2016 · Open in CIViC

In a study of metastatic colorectal cancer patients who received 5-FU-based first-line chemotherapy, those with BRAF V600E mutations had reduced progression-free survival (4.3mo vs. 12.5mo, HR:4.9, 95… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for BRAF exon 15 mutations. … (full text at CIViC)

PMID 19903786 · He et al., 2009 · Open in CIViC

CRISPR-mediated correction of endogenous BRAF p.V600E to wild type in patient-derived colorectal cancer organoids abolished constitutive MEK/ERK signaling, restored epidermal growth factor dependence,… (full text at CIViC)

PMID 40687798 · El Bouazzaoui et al., 2025 · Open in CIViC

Intestinal induction of the murine BrafV637E allele (human equivalent BRAF p.V600E) resulted in persistent intestinal hyperplasia, followed by development of murine serrated precursor lesions, serrate… (full text at CIViC)

PMID 29235923 · Bond et al., 2018 · Open in CIViC

In Villin-Cre;BRAF p.V600E mice, dextran sulfate sodium (DSS)-induced colitis cooperated with BRAF p.V600E to induce cecal tumor formation, with cecal adenomas developing in 83% of mice 3 months after… (full text at CIViC)

PMID 38188365 · Gao et al., 2024 · Open in CIViC

In murine colonic organoids, BRAF p.V600E induced transient proliferation, disrupted epithelial organization, and activated a fetal-like dedifferentiation transcriptional program. Co-expression of TP5… (full text at CIViC)

PMID 32792685 · Reischmann et al., 2020 · Open in CIViC

In an inducible mouse model, intestinal expression of BRAF p.V600E induced persistent crypt hyperplasia, altered epithelial differentiation, and transcriptional programs associated with proliferation,… (full text at CIViC)

PMID 37735514 · Rzasa et al., 2023 · Open in CIViC

Of metastatic colorectal cancer patients treated with bevacizumab-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=… (full text at CIViC)

PMID 19571295 · Tol et al., 2009 · Open in CIViC

In a phase III trial, patients with BRAF V600E mutated metastatic colorectal cancer received triplet combination with encorafenib + binimetinib + cetuximab in a second or third-line setting. In the sa… (full text at CIViC)

Open in CIViC

This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, a… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In metastatic colorectal cancer patients with wildtype KRAS status who received cetuximab therapy, those with a BRAF V600E mutation had reduced progression-free survival (8.0wk vs. 31.4wk, P=0.001, lo… (full text at CIViC)

PMID 19884556 · Laurent-Puig et al., 2009 · Open in CIViC

In metastatic colorectal cancer patients with wildtype KRAS status who received cetuximab therapy, those with a BRAF V600E mutation had reduced progression-free survival (8.0wk vs. 31.4wk, P=0.001, lo… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to b… (full text at CIViC)

PMID 26989027 · Hsu et al., 2016 · Open in CIViC

Cell growth of several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell lines with activating BRAF mutations were insensitive, … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, bevacizumab, and cetuximab those with BRAF V600E mutations had reduced progression-free survival (6.6mo vs. … (full text at CIViC)

PMID 19571295 · Tol et al., 2009 · Open in CIViC

In a single-arm phase 1/2 trial in microsatellite stable BRAF V600E metastatic colorectal cancer (NCT04017650; n = 26), combination encorafenib + cetuximab + nivolumab achieved an ORR of 50 % among ev… (full text at CIViC)

PMID 40882637 · Morris et al., 2025 · Open in CIViC

In this trial, 665 patients having metastatic colorectal cancer were randomly assigned in 1:1:1 ratio to receive encorafenib plus cetuximab plus binimetinib, encorafenib plus cetuximab, investigators'… (full text at CIViC)

PMID 33503393 · Tabernero et al., 2021 · Open in CIViC

In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E and wildtype NRAS/KRAS (n=14) mutation treated with FOLFOX4 plus cetuximab were associat… (full text at CIViC)

PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC

In a retrospective study of 68 irinotecan-refractory metastatic colorectal cancer patients, the tumors of eight patients harbored BRAF V600E but were wildtype for KRAS codons 12, 13, 61 and 146 mutati… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies… (full text at CIViC)

PMID 25989278 · Rowland et al., 2015 · Open in CIViC

In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600… (full text at CIViC)

PMID 22608338 · Falchook et al., 2012 · Open in CIViC

In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy o… (full text at CIViC)

PMID 29431699 · Corcoran et al., 2018 · Open in CIViC

In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and pho… (full text at CIViC)

PMID 23549875 · Coffee et al., 2013 · Open in CIViC

The results showed that cell lines with BRAF(V600E) or KRAS(G13D) mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF were particularly sensitive to BMS-754807 if they hav… (full text at CIViC)

PMID 25527633 · Huang et al., 2015 · Open in CIViC

665 patients with BRAF V600E-mutated metastatic CRC were enrolled In this open-label, phase 3 trial. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab… (full text at CIViC)

PMID 31566309 · Kopetz et al., 2019 · Open in CIViC

The open-label phase 3 BEACON CRC trial included 665 patients with BRAF V600E-mutated metastatic CRC. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuxima… (full text at CIViC)

PMID 31566309 · Kopetz et al., 2019 · Open in CIViC

In the randomized phase 3 BREAKWATER trial, previously untreated patients with BRAF V600E-mutated metastatic colorectal cancer receiving first-line encorafenib, cetuximab, and mFOLFOX6 (n=236) had sig… (full text at CIViC)

PMID 40444708 · Elez et al., 2025 · Open in CIViC

The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Among metastatic colorectal cancer patients treated with cetuximab and irinotecan, those with BRAF V600E mutations were less likely to achieve a complete or partial response to therapy (0% , P=0.016, … (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than those with wildtype BR… (full text at CIViC)

PMID 19001320 · Di Nicolantonio et al., 2008 · Open in CIViC

In this case series, the authors assessed the efficacy and safety of swapping cetuximab for panitumumab as some patients are unable to tolerate treatment with the mouse/human chimeric monoclonal IgG1 … (full text at CIViC)

PMID 35970034 · Rausch et al., 2022 · Open in CIViC

Proteomic analysis of BRAFV600E in melanoma and CRC cell lines revealed a greater sensitivity to combination therapy approach with either PI3K and methyltransferase inhibitors along with PLX4720 (Vemu… (full text at CIViC)

PMID 23251002 · Mao et al., 2013 · Open in CIViC

Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth a… (full text at CIViC)

PMID 23845441 · Rad et al., 2013 · Open in CIViC

In an in vitro study, WiDr, HT-29 and RKO cell lines expressing BRAF V600E mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-typ… (full text at CIViC)

PMID 26865419 · Takigawa et al., 2016 · Open in CIViC

Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.

PMID 19001320 · Di Nicolantonio et al., 2008 · Open in CIViC